Infusion to Reduce Relapses in Childhood Nephrotic Syndrome

Gazyva is an intravenous CD20-directed antibody (obinutuzumab). On 25 September 2026, FDA approved it to reduce the risk of relapse in adults and children 2 years of age and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome (INS) who are in complete remission (US Prescribing Information, recent major change 9/2026, indication 1.4). It is given as four infusions in a clinic that can manage infusion reactions. It is not a home injection, not a cure, and not a reason to stop steroids or other immunosuppressants without the nephrology clinic. Marketed in the United States by Genentech, Inc., a member of the Roche Group (U.S. License No. 1048 on the prescribing information).

Distinct path — not this use: The same brand is also approved for previously untreated chronic lymphocytic leukemia (with chlorambucil), certain follicular lymphoma uses, and active lupus nephritis in adults who are receiving standard therapy. Those are different diseases, different schedules, and different evidence. A lupus nephritis, leukemia, or lymphoma plan is not this INS indication. Rituximab and other B-cell antibodies are not interchangeable with Gazyva by brand name.

Where this is taking place

Commercial door today: United States. FDA announced the INS approval on 25 September 2026. The Genentech prescribing-information PDF (revised with the INS indication in 9/2026) is the dose and eligibility source. The product is the existing 1,000 mg/40 mL single-dose vial (NDC 50242-070-01 on the prescribing information). The 25 September 2026 Genentech statement does not give a separate INS launch date. Ask the nephrology clinic whether the vial is stocked at an infusion site that can treat infusion reactions.

Who gives it: A pediatric or adult nephrology clinic that can confirm childhood-onset frequently relapsing or steroid-dependent INS, confirm complete remission before the first dose, screen for hepatitis B, and infuse the drug. Suspected side effects: Genentech 1-888-835-2555 or FDA MedWatch 1-800-FDA-1088 (company statement and MedWatch line).

Trial that supported the label: INShore / INSHORE — NCT05627557. Phase 3, randomized, open-label, obinutuzumab versus oral mycophenolate mofetil (MMF). Sponsor on ClinicalTrials.gov: Hoffmann-La Roche. Status checked 30 September 2026: active, not recruiting (primary completion 4 September 2025). Sites were in the United States, Belgium, Brazil, China, France, Italy, Japan, Poland, and Spain. A completed trial site is not a new-patient enrollment door and not a marketing authorisation in that country.

Outside the United States: Health Canada, EMA/European Commission, MHRA, TGA, PMDA/MHLW, Swissmedic, and NMPA authorisation of Gazyva/Gazyvaro for this INS use is not confirmed on sources used here. A draft CHMP agenda for 14–17 September 2026 listed a Gazyvaro variation (EMA/VR/0000349826) to extend the indication to childhood-onset INS, with action “For adoption.” An agenda item is not a CHMP opinion and not a European Commission decision. Do not import on your own.

Approval matrix

Access by country

• United States: Ask a nephrology clinic whether the person is in the FDA population: age 2 or older, childhood-onset INS that is frequently relapsing or steroid-dependent, and in complete remission now. Path: confirm remission and rule out a different kind of nephrotic syndrome the clinic thinks does not fit → hepatitis B screen → schedule four intravenous infusions (start, week 2, week 24, week 26) with premedication → plan steroid taper only with the clinic → ask the plan whether this indication is covered. No list price or copay dollars in this article.
• Canada / EU / UK / Australia / Japan / other countries: Authorisation not confirmed for this INS use. A trial site or a US vial is not home authorisation.
• If your regulator has not authorised it: do not import on your own.

Who is eligible

United States (prescribing information, INS section revised 9/2026):

• Indication: Reduce the risk of relapse in adult and pediatric patients 2 years of age and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome who are in complete remission.
• Pediatrics: Safety and effectiveness for this use are established in patients aged 2 years and older, supported by INSHORE, which enrolled 81 pediatric patients aged 2 years and older. Not established under 2 years.
• Complete remission at the start (how INSHORE defined it, and the label requires complete remission before dosing): no edema, urine protein-to-creatinine ratio (UPCR) 0.2 g/g or less, and trace or negative urine dipstick on 3 consecutive days in the week before randomisation in the trial. The label also says data are insufficient to recommend a dose for people who relapse during or after Gazyva.
• Weight-based dose: 1,000 mg IV if weight is 45 kg or more; 20 mg/kg IV if weight is under 45 kg.
• Contraindication: Known hypersensitivity (for example anaphylaxis) to obinutuzumab or any excipient, including serum sickness with prior obinutuzumab.
• Do not start during an active infection. History of recurring or chronic infections may raise infection risk.
• Hepatitis B: Screen before treatment. Monitor if the screen is positive. Hepatitis B can reactivate and can cause liver failure and death.
• Live vaccines: For childhood-onset INS, give age-appropriate live vaccines at least 28 days before the first dose. Do not give live-virus vaccines during treatment or until B-cell recovery is confirmed.
• Pregnancy and breastfeeding: Can cause B-cell depletion in a fetus. Effective contraception during treatment and for 6 months after the last dose. Do not breastfeed during treatment and for 6 months after the last dose.
• Older adults: The INS studies did not include enough people 65 and older ( 0 patients) to say whether they respond differently.

Not this indication, on the sources used here:

• Steroid-resistant, secondary, or known genetic nephrotic syndrome were excluded from INSHORE. The FDA indication is frequently relapsing or steroid-dependent childhood-onset INS in complete remission, not every protein-in-the-urine diagnosis.
• People who already failed MMF (2 or more relapses in 6 months) were excluded from the trial. The label does not create a separate “after MMF failure” schedule.
• Chronic lymphocytic leukemia, follicular lymphoma, and adult lupus nephritis uses of the same brand.
• Children under 2 years.
• A home or push injection. It is intravenous infusion only, by a healthcare professional who can treat severe infusion reactions.

What the pivotal study showed (INShore / NCT05627557)

Use the US prescribing information (section 14.4 and Table 23) for a prescription conversation. The FDA announcement and the Genentech statement match the direction of the result. The trial was open-label (not placebo-blinded).

Design: 85 patients, ages 2 to 25 in the trial entry rules, randomised 1:1 to intravenous Gazyva on day 1, day 15, week 24, and week 26, or oral MMF titrated to a target 1,200 mg/m²/day in two doses (maximum 2,000 mg/day) by week 4. Diagnosis of frequently relapsing or steroid-dependent nephrotic syndrome before age 18, normal eGFR for age, complete remission at entry, and at least one relapse in the prior 6 months. Median age 9 years (range 2 to 22); 64% were 2 to under 12; 65% male; 45% frequently relapsing and 55% steroid-dependent; 85% were on glucocorticoids at baseline. Steroids were tapered off by weeks 4–6 (no later than week 8) in the protocol.

Primary endpoint: No relapse after week 8 and complete remission at week 52 (first-morning UPCR ≤ 0.2 g/g). People were also counted as non-responders if they used systemic corticosteroids for more than 14 days in a 30-day period after week 8, started other rescue therapy, died, or had a missing week-52 UPCR.

Result (Table 23): 42/44 (95%) on Gazyva versus 30/41 (73%) on MMF. Adjusted difference 22 percentage points (95% CI 6 to 38); p = 0.004.

Key secondary results in the same table:

• First relapse: 4 events (7 per 100 patient-years) versus 15 (33 per 100 patient-years). Hazard ratio 0.25 (95% CI 0.08 to 0.75); p = 0.007.
• Total relapses from randomisation to week 52: 4 versus 24. Adjusted rate ratio 0.16 (95% CI 0.05 to 0.44); p = 0.0005.

B cells (section 12.2): In evaluable patients aged 4 and older, 43/43 (100%) were B-cell depleted at week 4 (CD19+ count under 10 cells/µL), 40/42 (95%) at week 52, and 8/22 (36%) still depleted at week 76. That long depletion is why live vaccines wait for confirmed recovery.

How it is taken

The prescribing information (section 2.5 and Table 6), not a press release, sets the INS dose.

Safety (what the label puts first)

Boxed warning:

1. Hepatitis B reactivation, including fulminant hepatitis, liver failure, and death. Screen everyone before the first dose. Monitor people who have hepatitis B. Stop Gazyva if hepatitis B reactivates.
2. Progressive multifocal leukoencephalopathy (PML), including fatal PML. New confusion, trouble talking or walking, dizziness, loss of balance, or vision change needs urgent care.

Other warnings that matter for this use: infusion reactions (can be fatal in the product warning; premedicate and monitor); hypersensitivity including serum sickness (permanent stop); serious infections (do not treat an active infection); neutropenia (blood counts); avoid live vaccines until B cells recover; fetal B-cell depletion.

In INSHORE (44 people on Gazyva, 41 on MMF): no Grade 5 (fatal) adverse reactions. Infections in 89% on Gazyva versus 76% on MMF. All infusion reactions were Grade 1–2 and mostly with the first infusion; 23% needed the infusion interrupted, slowed, or stopped. Common symptoms of those reactions: fever, vomiting, nausea.

Adverse reactions at ≥10% on Gazyva (Table 15, all grades): upper respiratory infection 59% (MMF 63%), infusion reaction 36%, ear infection 32% (15%), pneumonia 25% (5%; Grade 3–4 9% vs 0%), influenza 20% (10%), neutropenia 18% (2%; Grade 3–4 16% vs 2%), bronchitis 14% (5%), COVID-19 14% (12%), conjunctivitis 14% (7%), urinary tract infection 11% (0%). A footnote says neutrophil counts under 1,000 cells/µL occurred in 8 (18%) versus 2 (5%).

How to talk to a doctor

Bring: the age when protein first spilled into the urine, whether relapses are frequent or steroid-dependent (dates and steroid doses), the latest urine protein and albumin, kidney function, swelling now or not, hepatitis B history, vaccines (especially live vaccines in the last month), prior rituximab or other B-cell antibodies, prior MMF, infections, and pregnancy plans.

Ask: “Are we in complete remission, and is this the FDA population for Gazyva — age 2 or older, childhood-onset, frequently relapsing or steroid-dependent INS?” Ask where the four infusions would happen, how steroids would be tapered, how long B cells may stay low (the label still found depletion in some people at week 76), and when live vaccines can restart. Ask the insurer whether this indication is covered. Do not start, stop, or import the drug on your own.

Research and regulatory team

• US marketing authorisation holder on the prescribing information: Genentech, Inc., a member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990. U.S. License No. 1048.
• INShore sponsor (ClinicalTrials.gov): Hoffmann-La Roche. Overall official listed as Clinical Trials, study director, Hoffmann-La Roche. No named physician investigator is on that public record.
• FDA announcement: approval for this INS use, 25 September 2026, with Breakthrough Therapy, Orphan Drug, and Priority Review designations. Public contact 1-888-INFO-FDA.
• Named on the Genentech statement only (company, not the trial registry): Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development; Andi Callaway, founder and president, The Nephrotic Syndrome Foundation.

Canada zoom: INS authorisation not confirmed

Gazyva for childhood-onset idiopathic nephrotic syndrome is not confirmed as a Health Canada authorisation on sources used here. A US prescribing information PDF is not a Canadian Product Monograph. INShore sites in other countries are not a Canadian notice of compliance. Ask the Canadian nephrology clinic what legal options exist. Do not import a US vial on your own.

EU zoom: agenda item is not an EC decision

Gazyvaro for this INS use is not confirmed as an EMA or European Commission authorisation. The draft CHMP agenda for 14–17 September 2026 listed variation EMA/VR/0000349826 (extension toward childhood-onset INS, based on INShore) as “For adoption.” That is a meeting agenda, not a published opinion and not a Commission decision. EU trial sites do not replace that decision. Do not import on your own.

Bottom line

Gazyva is a US-approved intravenous option to lower relapse risk in people 2 years and older with frequently relapsing or steroid-dependent childhood-onset INS who are already in complete remission. INShore showed 95% versus 73% still relapse-free after week 8 and in remission at one year, against oral MMF, with infection, infusion reactions, low white cells, hepatitis B, and PML as the safety issues to plan for. The near-term path is a nephrology infusion clinic in the United States — not a home shot, not a different Gazyva disease, and not an assumption that another country or a benefit plan will pay.

Primary sources

• FDA announcement: drug for idiopathic nephrotic syndrome, patients 2 years and older (25 Sep 2026)
• Gazyva (obinutuzumab) Prescribing Information, Genentech PDF, INS sections revised 9/2026
• ClinicalTrials.gov NCT05627557 (INShore)
• Genentech statement, 25 Sep 2026 (company — not the regulator)
• Draft CHMP agenda, 14–17 Sep 2026 (Gazyvaro INS variation listed for adoption; not a decision)